Drug Type Bispecific antibody, Biosimilar |
Synonyms Faricimab Biosimilar (Wincal Biopharm Inc.), Faricimab Eye Drop(Wincal Biopharm), 法瑞西单抗滴眼液(Wincal Biopharm) + [1] |
Target |
Action inhibitors |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Age Related Macular Degeneration | Preclinical | United States | 22 May 2023 |